Staphylococcus aureus and Wegeners granulomatosis 英文参考文献.docVIP

Available online /content/4/2/077 Commentary Staphylococcus aureus and Wegener’s granulomatosis Eliane R Popa*, Coen A Stegeman?, Cees GM Kallenberg* and Jan Willem Cohen Tervaert? *Department of Clinical Immunology, University Hospital Groningen, The Netherlands ?Department of Nephrology, University Hospital Groningen, The Netherlands ?Department of Clinical Immunology, University of Maastricht, The Netherlands Correspondence: Prof. Dr CGM Kallenberg, Deptartment of Clinical Immunology, University Hospital Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. Tel: +31 50 3612945; fax: +31 50 3619069; e-mail: c.g.m.kallenberg@int.azg.nl Received: 17 September 2001 Revisions requested: 5 October 2001 Revisions received: 15 October 2001 Accepted: 18 October 2001 Arthritis Res 2002, 4:77-79 This article may contain supplementary data which can only be found online at /content/4/2/077 ? 2002 BioMed Central Ltd Published: 26 October 2001 (Print ISSN 1465-9905; Online ISSN 1465-9913) Abstract Wegener’s granulomatosis (WG) is a form of systemic vasculitis. It is characterized by granulomatous inflammation in the upper and lower airways, vasculitis and necrotizing glomerulonephritis, and is strongly associated with antineutrophil cytoplasmic antibodies against proteinase 3. Since the etiology of the disease is not clear, treatment, consisting of corticosteroids and immunosuppressives, is nonspecific and associated with severe side effects. Pinpointing the trigger(s) of the disease would highly improve treatment. Clinical evidence shows that an infectious agent, the bacterium Staphylococcus aureus, is a risk factor for disease relapse, suggesting its involvement in the pathogenesis of WG. Here we review both clinical and experimental data that either indicate or support a role for S. aureus in WG. Keywords: autoimmunity, co-trimoxazole, Staphylococcus aureus, superantigens, Wegener’s granulom